# A Study of the Pharmacokinetics and Safety of CS0159 in Subjects With Hepatic Injury

> **NCT06888115** · PHASE1 · COMPLETED · sponsor: **Cascade Pharmaceuticals, Inc** · enrollment: 24 (actual)

## Conditions studied

- Primary Biliary Cholangitis

## Interventions

- **DRUG:** CS0159

## Key facts

- **NCT ID:** NCT06888115
- **Lead sponsor:** Cascade Pharmaceuticals, Inc
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-03-13
- **Primary completion:** 2025-05-29
- **Final completion:** 2025-06-03
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2025-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06888115

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06888115, "A Study of the Pharmacokinetics and Safety of CS0159 in Subjects With Hepatic Injury". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06888115. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*